HPV阳性口咽癌的治疗降阶梯:系统综述与Meta分析
该系统综述与Meta分析纳入55项研究共38929例HPV阳性口咽癌患者,比较降阶梯治疗与标准治疗。结果显示降阶梯治疗降低总生存(HR=1.33)、无进展生存(HR=2.11)、局部区域控制(HR=2.51)和远处控制(HR=1.9)。作者认为不应在临床实践中广泛盲目采用降阶梯治疗。
要点
- 降阶梯治疗降低HPV阳性口咽癌总生存(HR=1.33,95%CI 1.17-1.52)。
- 降阶梯治疗降低无进展生存(HR=2.11,95%CI 1.65-2.69)。
- 作者认为不应广泛盲目采用降阶梯治疗。
核心结论
- 在HPV阳性口咽癌患者中,不应在临床实践中广泛盲目地采用降阶梯治疗,因为存在给予患者次优治疗的具体风险。
研究设计与样本
- 系统综述与Meta分析,检索至2020年9月,纳入提供降阶梯治疗与标准根治性治疗结局数据的前瞻性或回顾性研究。
- 共55项研究(来自1393篇筛选文献)用于定量合成,涉及38929例患者。
主要发现
- 在48项有可用数据的研究中,降阶梯治疗降低HPV阳性口咽癌的总生存(HR=1.33,95%CI 1.17-1.52;p<0.01)。
- 降阶梯治疗降低无进展生存(HR=2.11,95%CI 1.65-2.69;p<0.01)。
- 与标准治疗相比,降阶梯治疗与局部区域控制降低相关(HR=2.51,95%CI 1.75-3.59;p<0.01)。
- 与标准治疗相比,降阶梯治疗与远处控制降低相关(HR=1.9,95%CI 1.25-2.9;p<0.01)。
- 在根治性治愈性背景下,放化疗较单纯放疗改善生存(HR=1.42,95%CI 1.16-1.75;p<0.01)。
关键数值与推荐
- 降阶梯治疗 vs 标准治疗:总生存HR=1.33(95%CI 1.17-1.52;p<0.01)。
- 降阶梯治疗 vs 标准治疗:无进展生存HR=2.11(95%CI 1.65-2.69;p<0.01)。
- 降阶梯治疗 vs 标准治疗:局部区域控制HR=2.51(95%CI 1.75-3.59;p<0.01)。
- 降阶梯治疗 vs 标准治疗:远处控制HR=1.9(95%CI 1.25-2.9;p<0.01)。
- 放化疗 vs 单纯放疗:总生存HR=1.42(95%CI 1.16-1.75;p<0.01)。
临床怎么用
- 作者认为,在HPV阳性口咽癌患者中,不应在临床实践中广泛盲目地采用降阶梯治疗,因为存在给予患者次优治疗的具体风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Human Papillomavirus (HPV) related oropharyngeal carcinoma (OPC) carries a better prognosis compared with HPV-counterparts, thereby pushing the adoption of de-intensification treatment approaches as new strategies to preserve superior oncologic outcomes while minimizing toxicity. We evaluated the effect of treatment de-intensification in terms of overall survival (OS), progression-free survival (PFS), locoregional and distant control (LRC and DM) by selecting prospective or retrospective studies, providing outcome data with reduced intensification versus standard curative treatment in HPV+ OPC patients, with a systematic analysis till September 2020. The primary outcome of interest was OS. Secondary endpoints were PFS, LRC, and DM expressed as HR. A total of 55 studies (from 1393 screened references) were employed for quantitative synthesis for 38 929 patients. Among n = 48 studies with data available, de-intensified treatments reduced OS in HPV+ OPCs (HR = 1.33, 95% CI 1.17-1.52; p < 0.01). In de-escalated treatments, PFS was also decreased (HR = 2.11, 95% CI 1.65-2.69; p < 0.01). Compared with standard treatments, reduced intensity approaches were associated with reduced locoregional and distant disease control (HR = 2.51, 95% CI 1.75-3.59; p < 0.01; and HR = 1.9, 95% CI 1.25-2.9; p < 0.01). Chemoradiation improved survival in a definitive curative setting compared with radiotherapy alone (HR = 1.42, 95% CI 1.16-1.75; p < 0.01). When adjuvant treatments were compared, standard and de-escalation strategies provided similar OS. In conclusion, in patients with HPV+ OPC, de-escalation treatments should not be widely and agnostically adopted in clinical practice, as therein lies a concrete risk of offering a sub-optimal treatment to patients.
引用
- Petrelli F, Luciani A, Ghidini A, et al. Treatment de-escalation for HPV+ oropharyngeal cancer: A systematic review and meta-analysis. Head Neck. 2022. PMID: 35238114. doi:10.1002/hed.27019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。